Your browser version may not work well with NCBI's Web applications. More information here...
1: Cancer Res. 2007 Oct 15;67(20):9609-12.
Related Articles, Links
Click here to read Click here to read
Silent polymorphisms speak: how they affect pharmacogenomics and the treatment of cancer.

Sauna ZE, Kimchi-Sarfaty C, Ambudkar SV, Gottesman MM.

Laboratory of Cell Biology, Center for Cancer Research, National Cancer Institute, NIH and Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892, USA.

Polymorphisms in the human genome contribute to wide variations in how individuals respond to medications, either by changing the pharmacokinetics of drugs or by altering the cellular response to therapeutic agents. The goal of the emerging discipline of pharmacogenomics is to personalize therapy based on an individual's genotype. Due to the relatively large frequency of single-nucleotide polymorphisms (SNP) in the human genome, synonymous SNPs are often disregarded in many pharmacogenomic studies based on the assumption that these are silent. We have shown recently that synonymous SNPs in ABCB1 (P-glycoprotein), which is implicated both in determining drug pharmacokinetics and multidrug resistance in human cancer cells, can affect protein conformation and function. We discuss the importance of polymorphisms in drug metabolizing enzymes and transporters in anticancer therapy and suggest that synonymous polymorphisms may play a more significant role than is currently assumed.

Publication Types:
PMID: 17942888 [PubMed - indexed for MEDLINE]